What is IpiNovyx Bio?
IpiNovyx Bio is a biotechnology firm focused on the development of potent small molecule therapeutics. The company's pipeline targets autoimmune and inflammatory disorders, addressing critical unmet medical needs in these therapeutic areas. Headquartered in West Nyack, New York, IpiNovyx Bio is positioned to advance its innovative drug candidates through clinical development.
How much funding has IpiNovyx Bio raised?
IpiNovyx Bio has raised a total of $10M across 1 funding round:
Angel/Seed
$10M
Angel/Seed (2021): $10M with participation from Viva BioInnovator, Lilly, and Opaleye Management
Key Investors in IpiNovyx Bio
Viva BioInnovator
Viva BioInnovator is a collaborative platform and investment division of Viva Biotech Holdings, dedicated to supporting innovative biotech companies globally, with a focus on early-stage start-ups. They aim to develop transformative therapeutics by providing investment and incubation tracks.
Lilly
Lilly, a prominent pharmaceutical entity, is recognized for its extensive research and development in various therapeutic areas, including autoimmune and inflammatory diseases. Their participation suggests a strategic interest in novel small molecule approaches.
Opaleye Management
Opaleye Management is an investment firm that likely focuses on strategic capital allocation within the life sciences sector. Their involvement indicates confidence in IpiNovyx Bio's therapeutic development strategy and market potential.
What's next for IpiNovyx Bio?
The recent major strategic investment signals a pivotal phase for IpiNovyx Bio, likely enabling the company to accelerate its research and development efforts, expand its clinical trial programs, and potentially scale its operations. This infusion of capital is expected to fuel the progression of its ultra-potent small molecule therapeutics towards commercialization, solidifying its position in the competitive biopharmaceutical landscape.
See full IpiNovyx Bio company page
